Skip to main content
SpringerLink
Log in

Proliferation Independent Activation of Programmed Cell Death as a Novel Therapy for Prostate Cancer

  • Chapter
Apoptosis

Part of the book series: Pezcoller Foundation Symposia ((PFSO,volume 5))

Abstract

Since the work of Charles Huggins in the 1940s, it has been known that prostatic cancer often retains an androgen responsiveness for stimulation of its growth. Prostatic cancer is thus often highly responsive to androgen ablation therapy. Based upon this, patients with non-organ confined disease eventually require systemic androgen ablation therapy. Nearly all men with metastatic prostatic cancer treated with surgically or chemically induced castration have an initial, often dramatic, beneficial response to such androgen withdrawal therapy1. While this initial response is of substantial palliative value, essentially all treated patients eventually relapse to an androgen-insensitive state and succumb to the progression of their cancer unless they die of intercurrent disease first; cures, if any, are rare2. Because of this nearly universal relapse phenomenon, the annual death rate from prostatic cancer has not decreased at all over the subsequent 50 years since androgen withdrawal has become standard therapy3. Over the last 50 years, the superficially benign nature of androgen withdrawal therapy has tended to disguise the fact that metastatic prostatic cancer is still a fatal disease for which no therapy is available which effectively increases survival2,4.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. The Leuprolide Study Group, Leuprolide versus diethylstilbestrol for metastatic prostatic cancer, New Engl. J. Med. 311–1281-1286 (1984).

    Google Scholar 

  2. H. Lepor, A. Ross, and P.C. Walsh, The influence of hormonal therapy on survival of men with advanced prostatic cancer, J. Urol. 128:335 (1982).

    PubMed  CAS  Google Scholar 

  3. C. Boring, T. Squires, and T. Tong, Cancer Statistics, 1992, Ca-a Cancer Journal for Clinicians 42:19 (1993).

    Article  Google Scholar 

  4. D. Raghavan, Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs, Seminars in Oncology 15:371 (1988).

    PubMed  CAS  Google Scholar 

  5. A.A Sinha, C.E. Blackhard, and U.S. Seal. A critical analysis of tumor morphology and hormone treatment in the untreated and estrogen treated responsive and refractory human prostatic carcinoma. Cancer 40:2836 (1977).

    Article  PubMed  CAS  Google Scholar 

  6. G.R. Prout, B. Leiman, J.J. Daly, R.A. MacLoughlin, P.P. Griffin, and H.H Young, Endocrine changes after diethylstilbestrol therapy. Urology 7:148 (1976).

    Article  PubMed  CAS  Google Scholar 

  7. J.T. Isaacs and D.S. Coffey, Adaptation vs selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation as studies in the Dunning R-3327 H adenocarcinoma, Cancer Research 41:5070 (1981).

    PubMed  CAS  Google Scholar 

  8. J.T. Isaacs, Cellular factors in the development of resistance to hormonal therapy, In: Bruchovsky, N., Goldie, J, (eds), Drug and Hormone Resistance in Neoplasia I 139–156 , CRC Press, Boca Raton (1981).

    Google Scholar 

  9. J.T. Isaacs, The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 5:1 (1984).

    Article  PubMed  CAS  Google Scholar 

  10. J.T. Isaacs, Relationship between tumor size and curability of prostate cancer by combined chemohormonal therapy. Cancer Research 49:6290 (1989).

    PubMed  CAS  Google Scholar 

  11. S.E. Shackney, G.W. McCormack, and G.J. Cuchural, Growth rate patterns of solid tumors and their relationship to responsiveness to therapy. Annals of Internal Medicine 89:107 (1978).

    Article  PubMed  CAS  Google Scholar 

  12. B. Helpap, R. Steins, and P. Bruhl, Autoradiographic in vitro investigations on prostatic tissue with C-14 and H-3 thymidine double labeling method, Beitr. Pathol. anat. Allg. Pathol., 151:65 (1974).

    Article  CAS  Google Scholar 

  13. J. S. Meyers, G. Sufrin, and S.A. Maring, Proliferation activity of benign human prostate, prostatic adenocarcinoma and seminal vesicle evaluated by thymidine labeling, J. Urol., 128:1353 (1982).

    Google Scholar 

  14. R. Nemoto, K. Hattori, K. Uchida, T. Shimazui, Y. Nishijima, K. Koiso, and M. Harada, S-phase fraction of human prostate adenocarcinoma studies with in vivo bromodeoxyuridine labeling, Cancer (Phila.), 66:509 (1990).

    Article  CAS  Google Scholar 

  15. M.V. Sadi and E.R. Barrack, Determination of growth fraction in advanced prostate cancer by Ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy, Cancer (Phila.), 67:3065 (1991).

    Article  CAS  Google Scholar 

  16. J. Folkman, What is the evidence that tumors are angiogenesis-dependent? J. Natl. Cancer Inst. 82:4 (1990).

    Article  PubMed  CAS  Google Scholar 

  17. A.H. Wyllie, J.F.R. Kerr, and A.R. Currie, Cell death: the significance of apoptosis, International Reviews of Cytology 68:251 (1980).

    Article  CAS  Google Scholar 

  18. J.F.R. Kerr, A.H. Wyllie, and A.R. Currie. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br. J. Cancer, 26:239 (1972).

    Article  PubMed  CAS  Google Scholar 

  19. S.R. Umansky, B.A. Korol, and P.A. Nelipovich, In vivo DNA degradation in thymocytes of γ-irradiated or hydrocortisone-treated rats, Biochim. Biophys. Acta, 655:9 (1981).

    Article  CAS  Google Scholar 

  20. A.H. Wyllie, R.G. Morris, A.L. Smith, and D. Dunlop, Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis, J. Pathol., 142:66(1984).

    Article  Google Scholar 

  21. N. Kyprianou and J.T. Isaacs, Activation of programmed cell death in the rat ventral prostate after castration, Endocrinology, 122:552 (1988).

    Article  PubMed  CAS  Google Scholar 

  22. H.F. English, N. Kyprianou, and J.T. Isaacs, Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration, Prostate, 15:233 (1989).

    Article  PubMed  CAS  Google Scholar 

  23. N. Kyprianou, H.F. English, and J.T. Isaacs, Activation of a Ca2+-Mg2+-dependent endonuclease as an early event in castration-induced prostatic cell death, Prostate, 13:103 (1988).

    Article  PubMed  CAS  Google Scholar 

  24. N. Kyprianou, H.F. English, and J.T. Isaacs, Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation, Cancer Res., 50:3748 (1990).

    PubMed  CAS  Google Scholar 

  25. J.T. Isaacs, Antagonistic Effect of Androgen on Prostatic Cell Death, The Prostate 5:545 (1984).

    Article  PubMed  CAS  Google Scholar 

  26. N. Kyprinaou and J.T. Isaacs, Biological Significance of Measurable Androgen Levels in the Rat Ventral Prostate Following Castration, The Prostate 10:313 (1987).

    Article  Google Scholar 

  27. A.E. Pegg, D.H. Lockwood, and H.G. Williams-Ashman, Concentrations of Putrescine and Polyamines and their Enzymic Synthesis during Androgen-Induced Prostatic Growth, Biochem. J. 117:17(1970).

    PubMed  CAS  Google Scholar 

  28. P. Martikainen and J. Isaacs, Role of Calcium in the Programmed Death of Rat Prostatic Glandular Cells, The Prostate 17:175 (1990).

    Article  PubMed  CAS  Google Scholar 

  29. N. Kyprianou and J.T. Isaacs, Expression of transforming growth factor-ß in the rat ventral prostate during castration induced programmed cell death, Mol. Endocrinol. 3:1515 (1989).

    CAS  Google Scholar 

  30. N. Kyprianou and J.T. Isaacs, Identification of a cellular receptor for transforming growth factor-ß in rat ventral prostate and its negative regulation by androgens, Endocrinol. 123:2124 (1988b).

    Article  CAS  Google Scholar 

  31. P. Martikainen, N. Kyprianou, and J.T. Isaacs, Effect of Transforming Growth Factor-ß1 on Proliferation and Death of Rat Prostatic Cells, Endocrinol. 127:2963 (1990).

    Article  CAS  Google Scholar 

  32. R.D. Synder, Polyamine depletion is associated with altered chromatin structure in HeLa cells, Biochem. J. 260:697 (1989).

    Google Scholar 

  33. B. Brüne, P. Hartzeil, P. Nicotera, and S. Orrenius, Spermine prevents endonuclease activation and apoptosis in thymocytes, Exp. Cell Res. 195:323 (1991).

    Article  PubMed  Google Scholar 

  34. L.W.K. Chung and D.S. Coffey, Biochemical characterization of prostatic nuclei I. androgen-induced hanges in nuclear proteins, Biochimica. Biophysica. Acta 247:570 (1971).

    Article  CAS  Google Scholar 

  35. J.F.R. Kerr and J. Searle, Deletion of cells by apoptosis during castration-induced involution of the rat prostate, Virchows. Arch. [Cell Pathol] 13:87 (1973).

    CAS  Google Scholar 

  36. Y. Furuya and J.T. Isaacs, Differential gene regulation during programmed death (Apoptosis) versus proliferation of prostatic glandular cells induced by androgen manipulation, in press (1993).

    Google Scholar 

  37. V.E. Quarmby, W.C. Beckman, Jr., E.M. Wilson, and F.S. French, Androgen regulation of c-myc messenger ribonucleic acid levels in rat ventral prostate, Mol. Endocrinol. 1:865 (1987).

    Article  PubMed  CAS  Google Scholar 

  38. C. Chang, A.G. Saltzman, N.S. Sorensen, R.A. Hiipakka, and S. Liao, Identification of glutathione S-transferase Yb1 mRNA as the androgen repressed mRNA by cDNA cloning and sequence analysis, J. Biol. Chem. 262:11901 (1987).

    PubMed  CAS  Google Scholar 

  39. M.L. Montpetit, K.R. Lawless, and M. Tenniswood, Androgen Repressed Messages in the Rat Ventral Prostate, Prostate 8:25 (1986).

    Article  PubMed  CAS  Google Scholar 

  40. R. Buttyan, Z. Zakeri, R. Lockshin, and D. Wolgemuth, Cascade induction of c-fos, c-myc and heat shock 70K transcripts during regression of the rat ventral prostate gland, Mol. Endocrinol., 2:650 (1988).

    Article  PubMed  CAS  Google Scholar 

  41. R. Buttyan, C.A. Olsson, J. Pintar, C. Chang, M. Bandyk, P-Y Ng, and I.S. Sawczuk, Induction of the TRPM-2 gene in cells undergoing programmed death, Mol. Cell Biol. 9:3473 (1989).

    PubMed  CAS  Google Scholar 

  42. D.R. Dowd, P.N. MacDonald, B.S. Komm, M.R. Haussler, and R. Miesfeld, Evidence for early induction of calmodulin gene expression in lymphocytes undergoing glucocorticoid-mediated apoptosis, J. Biological Chemistry 266:18423 (1991).

    CAS  Google Scholar 

  43. L. Fesus, V. Thomazy, and A. Falus, Induction and activation of tissue transglutaminase during programmed cell death, FEBS Lett. 224:104 (1989).

    Article  Google Scholar 

  44. D.S. Coffey, J. Shimazaki, and H.G. Williams-Ashman, Polymerization of deoxyribonucleotides in relation to androgen-induced prostatic growth, Arch. Biochem. Biophys. 124:184 (1968).

    Article  CAS  Google Scholar 

  45. Y. Gavrieli, Y. Sherman, and S.A. Ben-Sasson, Identification of Programmed Cell Death In Situ via Specific Labeling of Nuclear DNA Fragmentation, J. Cell Biol. 119:493 (1992).

    Article  PubMed  CAS  Google Scholar 

  46. R. S. Berges, Y. Furuya, L. Remington, H.F. English, T. Jacks, and J.T. Isaacs, Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation, Proc. Natl. Acad. Sci. (USA), (in press, 1993).

    Google Scholar 

  47. R. Stiens and Helpap, Regressive changes in the prostate after castration. A study using histology, morphometrics and autoradiography with special reference to apoptosis, Pathol. Res. Pract. 172:73 (1981).

    Article  PubMed  CAS  Google Scholar 

  48. G.S. Evans and J.A. Chandler, Cell proliferation studies in the rat prostate: II. The effects of castration and androgen replacement upon basal and secretory cell proliferation, Prostate 11:339 (1987).

    Article  PubMed  CAS  Google Scholar 

  49. H.F. English, J.R. Drago, and R.J. Santen, Cellular response to androgen depletion and repletion in the rat ventral prostate: Autoradiography and morphometric analysis, The Prostate 7:41 (1985).

    Article  PubMed  CAS  Google Scholar 

  50. S. Lowe, EM. Schmitt, S.W. Smith, B.A. Osborne, and T. Jacks, p53 is required for radiation induced apoptosis in mouse thymocytes, Nature 362:847 (1993).

    Article  PubMed  CAS  Google Scholar 

  51. R. Berges and J.T. Isaacs, Programming events in the regulation of cell proliferation and death, Clinical Chemistry 39:2 (1993).

    Google Scholar 

  52. N. Kyprianou and J.T. Isaacs, Thymine-less death in androgen independent prostatic cancer cells, Biochem. Biophys. Res. Commun. 165:73 (1989).

    Article  CAS  Google Scholar 

  53. P. Martikainen, N. Kyprianou, R.W. Tucker and J.T. Isaacs, Programmed death of non-proliferating androgen independent prostatic cancer cells, Cancer Res. 51:4693 (1991).

    PubMed  CAS  Google Scholar 

  54. S.B. Christensen, E. Norup E and U. Rasmussen, Chemistry and structure-activity relationship of the histamine secretagogue Thapsigragin and related compounds, In: Natural Products and Drug Development (Editors: P. Krogsgaard-Larsen, S. Brogger Christensen, H. Kofod) pp. 405 (1993).

    Google Scholar 

  55. U. Rasmussen, S.B. Christensen, and F. Sandberg, Thapsigargin and thapsigargicin, two new histamine liberators from Thapsia garganica. L. Acta. Pharm. Suec. 15, 133 (1978).

    CAS  Google Scholar 

  56. O. Thastrup, P.J. Cullen, B.K. Dr_bak, M.R. Hanley, and A.P. Dawson, Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2+-ATPase, Proc. Natl. Acad. Sci. USA, 87:2466 (1990).

    Article  PubMed  CAS  Google Scholar 

  57. J. Lytton, M. Westlin, and M.R. Haley, Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps, J. Biol. Chem. 266:17067 (1991).

    PubMed  CAS  Google Scholar 

  58. A. Christensson, C.B. Laurell, and H. Lilja, Enzymatic activity of the prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors, Europe J. Biochem. 194:755 (1990).

    Article  CAS  Google Scholar 

  59. L.D. Papsidero, M. Kuriyama, M.C. Want, J. Horoszewicz, S.S. Leong, L. Valenzuela, et al. Prostate antigen: a marker for human prostate epithelial cells, J. Natl. Cancer Inst. 66:37 (1981).

    PubMed  CAS  Google Scholar 

  60. H. Lilja. C. Christensson, U. Dahlen, M-T. Martikainen, O. Nilsson, K. Pettersson, et al, Prostate-specific antigen in human srum occurs predominately in complex with α1-antichymotrypsin, Clin. Chem. 37:618(1991).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Johns Hopkins Oncology Center and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

    Yuzo Furuya, Richard S. Berges, Per Lundmo & John T. Isaacs

Authors
  1. Yuzo Furuya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard S. Berges
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Per Lundmo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John T. Isaacs
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Roswell Park Cancer Institute, Buffalo, New York, USA

    Enrico Mihich

  2. Stanford University, Stanford, California, USA

    Robert T. Schimke

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer Science+Business Media New York

About this chapter

Cite this chapter

Furuya, Y., Berges, R.S., Lundmo, P., Isaacs, J.T. (1994). Proliferation Independent Activation of Programmed Cell Death as a Novel Therapy for Prostate Cancer. In: Mihich, E., Schimke, R.T. (eds) Apoptosis. Pezcoller Foundation Symposia, vol 5. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9217-1_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-9217-1_9

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4757-9219-5

  • Online ISBN: 978-1-4757-9217-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation